VHH-based tolerance induction platform targeting MHCII

The "VHH-based tolerance induction platform targeting MHCII" is an experimental immunotherapy approach that uses single-domain antibody fragments (VHHs or nanobodies) engineered to specifically bind major histocompatibility complex class II (MHCII) molecules on antigen-presenting cells. By conjugating these nanobodies with disease-relevant antigens or immunosuppressive agents (such as dexamethasone), the platform aims to induce antigen-specific immune tolerance. This strategy has demonstrated efficacy in preclinical models of autoimmune diseases such as experimental autoimmune encephalomyelitis (EAE), type 1 diabetes, and T cell-mediated arthritis by selectively delivering tolerogenic signals to MHCII-positive cells and modulating immune responses without broad immunosuppression. The approach leverages the unique properties of nanobodies for targeted delivery and site-specific modification[1][2].

Other names

nanobody–MHCII tolerance platformVHH–MHCII conjugate